|
|
Marketing Authorisations
|
|
|
|
|
Effective against symptoms, but no long-term evaluation
|
|
|
|
|
|
|
|
|
|
Premature marketing authorisation
|
|
|
|
|
|
|
|
|
|
|
|
Higher transplant rate, but fatal adverse effects
|
|
|
|
|
|
|
|
|
|
Very similar to nivolumab
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
Too many harms and too little efficacy
|
|
|
|
|
|
|
|
|
|
Paracetamol alone is the first choice
|
|
|
|
|
|
|
|
|
|
Aspirin as primary prevention: a narrow margin between benefits and harms
|
|
|
|
|
|
|
|
|
|
A weak or uncertain effect on survival, with a risk of serious adverse effects
|
|
|
|
|
|
|
|
|
|
|
|